Navigation Links
Neptune Reports Year End Financial Results - Neptune Records 18% Sales Increase and 43% EBITDA Increase in Year End Results
Date:9/28/2007

LAVAL, QC, Sept. 28 /PRNewswire-FirstCall/ - Neptune Technologies & Bioressources Inc. (NASDAQ.NEPT - TSX.V.NTB), is pleased to report its financial results for the fiscal year ended May 31, 2007. During the last fiscal year, Neptune improved its productivity and operational profitability while continuing its business development strategy to penetrate the American, European and Asian markets, resulting in sustainable sales growth.

Financial Results and Highlights:

- Sales increased by 18% to $8,126,000 from $6,912,000 in the preceding

fiscal year.

- EBITDA increased by 43% to $1,504,000 from $1,049,000 in the preceding

fiscal year, representing a third consecutive year with a positive

EBITDA.

- EBITDA margin reached 18.5%, compared to 15.2% in the preceding fiscal

year.

- Excluding stock-based compensation expenses, Neptune would have

realized earnings of $152,000 instead of a loss of $2,677,000 in the

fiscal year ended May 31, 2007. Excluding stock-based compensation

expenses and an extraordinary gain from the settlement of debentures,

Neptune would have realized a loss of $1,574,000 instead of a loss of

$886,000 in the fiscal year ended May 31, 2006.

"We believe that the evaluation model and accounting method for stock-based compensation expenses are not appropriate for small capitalization fast growing companies. They do not bring the accounting value of stock-based compensation closer to the market value, as they should and as they were implemented for", stated Xavier Harland, Director of Finance.

"Neptune has managed to increase its EBITDA by $455,000 with a $1.2M increase in sales, confirming its improvement in operational efficiency", stated Andre Godin, Vice-President, Administration and Finance.

Neptune continues to strongly support its strategic development plan to pursue partnerships/strategic alliances with worldwide leaders in the nutraceutical and pharmaceutical industries. In accordance with its plan, Neptune has signed agreements with Nestle and Yoplait, paving the way for its entrance into the global functional food market. Neptune is in negotiations with pharmaceutical companies with the short-term objective of penetrating the pharmaceutical market.

About Neptune Technologies & Bioressources Inc.

http://www.neptunebiotech.com

Neptune Technologies & Bioressources Inc. develops proprietary and potent health ingredients from underexploited marine biomasses, such as krill, with its patented extraction process (Neptune OceanExtract(TM)). Using its proprietary process, Neptune Technologies & Bioressources Inc. is strategically positioning itself in the health and wellness market.

Natural biomass extraction is now playing an important role in developing nutrigenomics, the next wave in nutritional research. Through strategic alliances and partnerships, as well as through clinical studies, the Company continues to demonstrate the immense beneficial effects of these products. The Company develops and markets new formulas and new products for specific applications in high growth markets such as the nutraceutical, cosmeceutical, biopharmaceutical and nutrigenomics markets.

TSX venture exchange does not accept responsibility for the adequacy or

accuracy of this press release.

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports filed with the Securities and Exchange Commission.


'/>"/>
SOURCE NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... United States multicenter, prospective clinical study that demonstrates the accuracy of the ... of identifying clinically significant acute bacterial and viral respiratory tract infections by ...
(Date:10/12/2017)... (PRWEB) , ... October 12, ... ... ) has launched Rosalind™, the first-ever genomics analysis platform specifically designed for ... complexity. Named in honor of pioneering researcher Rosalind Franklin, who made a ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... Personal eye wash is a basic first ... eye at a time. So which eye do you rinse first if a dangerous substance ... Plum Duo Eye Wash with its unique dual eye piece. , “Whether its ...
(Date:10/11/2017)...  VMS BioMarketing, a leading provider of patient support solutions, ... Educator (CNE) network, which will launch this week. The VMS ... care professionals to enhance the patient care experience by delivering ... health care professionals to help women who have been diagnosed ... ...
Breaking Biology Technology:
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... Report on Form 10-K on Thursday April 13, 2017 with the ... The ... section of the Company,s website at http://www.nxt-id.com  under "SEC Filings," ... 2016 Year Highlights: Acquisition of ...
(Date:4/11/2017)... N.Y. , April 11, 2017 ... fingerprints, but researchers at the New York University ... College of Engineering have found that partial similarities ... security systems used in mobile phones and other ... thought. The vulnerability lies in the ...
(Date:4/5/2017)... -- KEY FINDINGS The global market for ... of 25.76% during the forecast period of 2017-2025. The ... the growth of the stem cell market. ... INSIGHTS The global stem cell market is segmented on ... stem cell market of the product is segmented into ...
Breaking Biology News(10 mins):